Brett R.  Hagen net worth and biography

Brett Hagen Biography and Net Worth

CAO of AlloVir
Brett R. Hagen is the Chief Accounting Officer at AlloVir.

What is Brett R. Hagen's net worth?

The estimated net worth of Brett R. Hagen is at least $60,422.74 as of February 8th, 2024. Mr. Hagen owns 79,347 shares of AlloVir stock worth more than $60,423 as of March 28th. This net worth approximation does not reflect any other assets that Mr. Hagen may own. Learn More about Brett R. Hagen's net worth.

How old is Brett R. Hagen?

Mr. Hagen is currently 51 years old. There are 6 older executives and no younger executives at AlloVir. The oldest executive at AlloVir is Mr. Vikas Sinha C.A., CPA, M.B.A., President, CFO & Director, who is 61 years old. Learn More on Brett R. Hagen's age.

How do I contact Brett R. Hagen?

The corporate mailing address for Mr. Hagen and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at [email protected]. Learn More on Brett R. Hagen's contact information.

Has Brett R. Hagen been buying or selling shares of AlloVir?

Over the course of the past ninety days, Brett R. Hagen has sold $12,153.21 in AlloVir stock. Most recently, Brett R. Hagen sold 11,150 shares of the business's stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $0.67, for a transaction totalling $7,470.50. Following the completion of the sale, the chief accounting officer now directly owns 79,347 shares of the company's stock, valued at $53,162.49. Learn More on Brett R. Hagen's trading history.

Who are AlloVir's active insiders?

AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.

Are insiders buying or selling shares of AlloVir?

In the last year, AlloVir insiders bought shares 1 times. They purchased a total of 2,930,870 shares worth more than $10,990,762.50. In the last year, insiders at the sold shares 36 times. They sold a total of 187,491 shares worth more than $310,339.72. The most recent insider tranaction occured on February, 8th when CAO Brett R Hagen sold 11,150 shares worth more than $7,470.50. Insiders at AlloVir own 40.0% of the company. Learn More about insider trades at AlloVir.

Information on this page was last updated on 2/8/2024.

Brett R. Hagen Insider Trading History at AlloVir

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/8/2024Sell11,150$0.67$7,470.5079,347View SEC Filing Icon  
2/5/2024Sell5,792$0.67$3,880.6490,497View SEC Filing Icon  
1/23/2024Sell901$0.67$603.6796,289View SEC Filing Icon  
1/4/2024Sell310$0.64$198.4097,190View SEC Filing Icon  
11/17/2023Sell403$1.63$656.89125,835View SEC Filing Icon  
10/19/2023Sell358$1.58$565.64126,595View SEC Filing Icon  
10/3/2023Sell222$1.98$439.56126,953View SEC Filing Icon  
8/17/2023Sell1,653$2.50$4,132.50127,175View SEC Filing Icon  
7/19/2023Sell342$3.56$1,217.52129,170View SEC Filing Icon  
6/9/2023Sell5,045$5.64$28,453.80129,512View SEC Filing Icon  
4/19/2023Sell348$3.71$1,291.08134,906View SEC Filing Icon  
1/19/2023Sell1,557$5.08$7,909.5674,342View SEC Filing Icon  
11/10/2022Sell5,989$8.00$47,912.0093,910View SEC Filing Icon  
10/24/2022Sell2,000$8.13$16,260.0099,899View SEC Filing Icon  
10/21/2022Sell11,334$8.45$95,772.30101,899View SEC Filing Icon  
10/19/2022Sell345$9.36$3,229.20113,233View SEC Filing Icon  
4/20/2022Sell276$6.68$1,843.6880,368View SEC Filing Icon  
1/20/2022Sell1,563$8.75$13,676.25View SEC Filing Icon  
2/22/2021Sell800$43.14$34,512.0064,765View SEC Filing Icon  
2/17/2021Sell2,320$40.42$93,774.4068,926View SEC Filing Icon  
See Full Table

Brett R. Hagen Buying and Selling Activity at AlloVir

This chart shows Brett R Hagen's buying and selling at AlloVir by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AlloVir Company Overview

AlloVir logo
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $0.76
Low: $0.74
High: $0.80

50 Day Range

MA: $0.72
Low: $0.67
High: $0.78

2 Week Range

Now: $0.76
Low: $0.62
High: $6.12

Volume

1,416,668 shs

Average Volume

1,374,193 shs

Market Capitalization

$87.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85